• SMAIO revenue for the first half of 2023 at €4.0 million, excluding intra-group operations1, up a sustained +203% thanks to the milestone payment of $3 million (~€2.8 million) from NuVasive
• Continued improvement in the margin on sales of implants outside the group to 67% vs. 63% in 2022 and 55% in 2021
• Solid cash position at €7.3 million as of June 30, 2023, excluding €1.5 million of non-dilutive financing obtained from SMAIO’s historic banks
Philippe ROUSSOULY, Chairman and CEO of SMAIO, declares: “During the first half of 2023, we effectively deployed our strategic plan in the United States by relying on our collaboration with NuVasive and on the training of local prescribing surgeons to enable the distribution of our i-kontrol offer. At the same time, we have improved our profitability indicators with a margin on implant sales reaching 67% thanks to the optimization of our purchasing conditions. Finally, we have implemented a targeted R&D policy which allows us to preserve our cash flow level with a view to our growing commercial strength. Building on these achievements, we approach the coming semesters with confidence by continuing the successful execution of our strategic plan which will primarily focus on increasing our sales and developing our profitability. »